Psychiatry and Clinical Psychopharmacology
Research Abstracts

Blood microRNA dysregulation in schizophrenia

1.

Afsin State Hospital, Psychiatry Clinic, Kahramanmaras - Turkey

2.

Department of Psychiatry, Harran University Training and Research Hospital, Sanliurfa-Turkey

3.

Balikli Gol State Hospital, Sanliurfa-Turkey

4.

Department of Medical Biology, Mersin University, Faculty of Medicine, Mersin-Turkey

5.

Department of Child and Adolescent Psychiatry, Celal Bayar University School of Medicine, Manisa, Turkey

6.

Cumra State Hospital, Konya-Turkey

7.

Department of Biostatistics, Mersin University, Faculty of Medicine, Mersin-Turkey

8.

Department of Psychiatry and Behavioral Sciences,University of Texas, Harris County Psychiatric Center, Texas-USA

Psychiatry and Clinical Psychopharmacology 2015; 25: Supplement S112-S112
Read: 854 Downloads: 510 Published: 12 February 2021

Objective: Schizophrenia is a devastating psychiatric disorder. Comprehensive research has been performed to identify biomarkers for this disease. Unfortunately we do not yet have a reliable biomarker for schizophrenia. MicroRNAs are 22-nucleotide-long RNA transcripts that regulate expression of genes at post-transcriptional level. To date, a limited number of studies has been done with peripheral tissue of schizophrenia patients. Here we demonstrate microRNA levels in plasma of schizophrenia patients.

Methods: Peripheral blood samples were collected from 16 schizophrenia patients and 16 healthy controls. Total RNA was extracted from Peripheral Whole Blood using Tri-Reagent (Sigma). Reverse transcriptase reactions contained 5 µl of extracted total RNA. QuantitativeComparative CT (ΔΔCT) Real-time PCR was performed in an ABI Prism 7500 Real-Time PCR System (Applied Biosystems) using SDS 2.0.6 software.

Results: Schizophrenia patients showed significant upregulation of five microRNAs: miR9-5p (p=0.002), miR29a-3p (p<0.001), miR106b5p (p=0.002), miR125a-3p(p<0.001) and miR125b-3p (p=0.018).

Conclusion: We found miR106b-5p upregulated in schizophrenia patients. Liu et al. compared 14 healthy controls with 16 depressed patients and found that miR106-5p and four other microRNAs were up regulated in the plasma of depressed patients. Additionally miR106b-5p was found to be downregulated in children with attention deficit / hyperactivity disorder(ADHD). In their unpublished study, Karababa et al. found miR106a-5p and miR106b-5p upregulated in manic patients. Perkins et al. found that miR-9-3p and miR-29a were downregulated and miR-106b was upregulated in the prefrontal cortex of individuals with schizophrenia. We believe combining our results with previous findings increases the likelihood the miR-106 family is disrupted in psychiatric disorders. Limitations of our study are small sample size, cross sectional design, and limited number of microRNA types. Despite these limitations, our study contributes to revealing potential peripheral microRNA signatures and encourages researchers to focus on this field.

Files
EISSN 2475-0581